Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
LB-2102 by Novartis for Neuroendocrine Carcinoma: Likelihood of Approval
LB-2102 is under clinical development by Novartis and currently in Phase I for Neuroendocrine Carcinoma. According to GlobalData, Phase I...
Data Insights
LB-2102 by Novartis for Small-Cell Lung Cancer: Likelihood of Approval
LB-2102 is under clinical development by Novartis and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...